GlassScriptPhysician profile
Heather Lee Close
NPI 1104297621
$1,039.48
in general payments reported to CMS, 2019-2025
19 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $129 · 2023: $270 · 2024: $132 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $372.02 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $93.93 | 2021-2025 | Bexsero |
| Sanofi-Aventis U.S. LLC | $68.38 | 2024-2025 | |
| Novo Nordisk INC | $65.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $62.38 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Collegium Pharmaceutical, INC. | $56.92 | 2025 | Jornay Pm |
| Abbvie INC. | $42.04 | 2021-2025 | |
| Dexcom, INC. | $38.60 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $35.29 | 2023 | |
| Adlon Therapeutics L.P. | $32.14 | 2021 | |
| Amgen INC. | $26.51 | 2021-2024 | Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $21.67 | 2024 | |
| Daiichi Sankyo INC. | $21.12 | 2021 | |
| Sanofi Pasteur INC. | $20.30 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.32 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $18.77 | 2022 | |
| Currax Pharmaceuticals LLC | $13.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Close listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.